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Clinicians have expressed a need for tools to assist in selecting
treatments for stroke prevention in patients with atrial fibrillation.
The objective of this study was to evaluate the impact of a compu-
terized antithrombotic risk assessment tool (CARAT) on general
practitioners’ prescribing of antithrombotics for patients with atri-
al fibrillation.
Methods
A prospective, cluster-randomized controlled trial was conducted
in 4 regions (in rural and urban settings) of general practice in
New South Wales, Australia (January 2012–June 2013). General
practitioner practices were assigned to an intervention arm (CAR-
AT) or control arm (usual care). Antithrombotic therapy prescrib-
ing was assessed before and after application of CARAT.
Results
Overall,  the antithrombotic therapies for 393 patients were re-
viewed  by  48  general  practitioners;  we  found  no  significant
baseline differences in use of antithrombotics between the control
arm and intervention arm. Compared with control patients, inter-
vention patients (n = 206) were 3.1 times more likely to be recom-
mended warfarin therapy (over any other treatment option; P <
.001) and 2.8 times more likely to be recommended any antico-
agulant (in preference to antiplatelet; P = .02). General practition-
ers agreed with most (75.2%) CARAT recommendations; CAR-
AT recommended that 75 (36.4%) patients change therapy. After
application of CARAT, the proportion of patients receiving any
antithrombotic therapy was unchanged from baseline (99.0%);
however,  anticoagulant  use  increased slightly  (from 89.3% to
92.2%), and antiplatelet use decreased (from 9.7% to 6.8%).
Conclusion
Tools such as CARAT can assist clinicians in selecting antithrom-
botic therapies, particularly in upgrading patients from antiplate-
lets to anticoagulants. However, the introduction of novel oral an-
ticoagulants has complicated the decision-making process, and
tools must evolve to weigh the risks and benefits of these new
therapy options.
Introduction
Treatment selection in the context of stroke prevention for people
with atrial fibrillation (AFib) has become more complex (1,2). The
increasing complexity is due in part to the challenges of treating
the at-risk elderly population, in whom AFib is most prevalent and
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risk of stroke greatest (3,4), and to an expanded range of treat-
ment options (ie, novel oral anticoagulants [NOACs]) used to rem-
edy some of the difficulties of anticoagulation associated with
warfarin (previously the mainstay therapy) (5). Although NOACs
offer some advantages, they are not devoid of risk (6), and their
high costs have given rise to recommendations for restricting their
use and for better supporting people who use warfarin (7).
Overall,  a  greater  range of  factors  must  now be considered in
weighing the risks and benefits of treatment, and this expanded
range  translates  to  a  more  complex  decision-making  process,
which further contributes to the suboptimal use of antithrombotic
therapy (8,9). This complexity adds to the burden of care in the
general  practice setting,  where general  practitioners (GPs) are
principally responsible for decision making and day-to-day man-
agement (10,11). Although strategies and resources (eg, point-of-
care testing, anticoagulation clinics, practice nurses, dedicated
home-based warfarin management services) for supporting the
management of anticoagulant therapy have been evaluated (12),
less attention has been paid to decision-making processes. Simple
scoring tools are available for GPs to assess the risks and benefits
of treatment, particularly for stroke risk assessment (13), but tools
to guide selection of treatment for patients are lacking (10,11).
A paper-based holistic risk-assessment algorithm for selecting
treatment significantly improved the use of antithrombotic ther-
apy (14). This algorithm was redeveloped into a Web-based com-
puterized antithrombotic risk assessment tool (CARAT). CARAT
facilitates a systematic review of risk factors and calculates the es-
timated risk-versus-benefit of therapy for each patient. Clinician
feedback has suggested the potential utility of CARAT in general
practice (15). The objective of this study was to evaluate the ef-
fect of CARAT on GPs’ prescribing of antithrombotic therapy.
We also assessed changes made to patients’ therapy and the level
of agreement on recommendations between GPs and CARAT.
Methods
We evaluated the effect of CARAT in a prospective, cluster-ran-
domized  controlled  clinical  trial  (trial  registration  no.  ACT-
RN12613000060741);  protocol details  are provided elsewhere
(16). Approval for the study was granted by the human research
ethics committees of the University of Technology Sydney, Uni-
versity of Sydney, and University of Newcastle.
GPs were recruited from 4 regions of general  practice in New
South Wales, Australia: the northern suburbs of Sydney, the Cent-
ral Coast, the Newcastle metropolitan area (in the Hunter Region),
and the rural areas of the Hunter Region. These regions encom-
pass rural and urban settings and have a high proportion of elderly
patients who are diverse in socioeconomic status, health status,
and access to health services.
GP practices were randomly allocated to one of 2 study arms, the
intervention arm or the control arm (Figure 1). GPs in the control
arm followed their usual practices; they used their own clinical
judgment, processes, and resources when reviewing and selecting
antithrombotic therapy for patients with AFib. GPs in the interven-
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Figure 1. Schematic outline of a cluster-randomized controlled trial of
a computerized antithrombotic risk assessment tool (CARAT) in a
sample of general practices in New South Wales, Australia, 2012.
 
CARAT assesses a patient’s stroke risk, bleeding risk, and medic-
ation-safety issues to quantify the patient’s estimated risk of stroke
versus bleeding, flag medication-management issues, and gener-
ate a recommendation for therapy (warfarin, aspirin, none, or oth-
er) (15). GPs in the intervention arm were asked to consider CAR-
AT output while reviewing the patient’s therapy and then make a
final decision to initiate, cease, or maintain current therapy. When
GPs disagreed with CARAT’s recommendations, the rationale for
disagreement was documented in CARAT. During the study, not
all NOACs were available or listed on the Australian Pharmaceut-
ical Benefits Scheme and hence were not listed as treatment op-
tions by CARAT (except  as  “other” therapy);  only dabigatran
(Pradaxa)  was  available  as  part  of  the  sponsoring  company’s
product familiarization program, which offered patients up to 12
months of therapy at no cost (17,18),
Family (general) practice-based GPs who practiced at one site (ie,
not at multiple sites) were recruited into the study from each re-
gion. They were randomly allocated through computer-generated
random allocation number sequences and then asked to recruit pa-
tients during a 3-month period, from January through March 2012.
Patients were selected for participation in the study if they were
eligible according to the following criteria:
Aged 65 years or older (ie, moderate to high risk of stroke by
definition)
•
Diagnosed with AFib, as confirmed by the GP (ie, pre-existing
or new onset, regardless antithrombotic therapy prescribed)
•
Able to provide informed written consent to participate•
The target sample size was 25 GPs for each study arm, with each
GP recruiting 5 to 10 patients (ie, up to 250 patients per study
arm), as estimated from previous data (8,14). This sample size ac-
counted for any clustering effects (a prior intracluster correlation =
0.03, 80% power) and a participant dropout rate of up to 20%
(19,20).
Data collection
A purpose-designed data collection form for classifying stroke risk
and bleeding risk was used by GPs and project officers to docu-
ment information on patient demographics, medical history (in-
cluding concurrent chronic diseases defined as non-self-limiting
conditions persisting for at least 3 months [21]), AFib, medication
management and safety issues, contraindications to warfarin ther-
apy, and antithrombotic therapy prescribed. The clinical informa-
tion required to assess stroke risk, bleeding risk, medication adher-
ence, potential for drug interactions, and medication-management
support needs were inputs for CARAT. Patients were assessed for
risk of stroke according to the CHADS2 Score for Atrial Fibrilla-
tion  Stroke  Risk  (25)  and  for  risk  of  bleeding  according  to
HEMORR2HAGES criteria (26) and categorized as being at low,
medium, or high risk. Factors affecting the decision to prescribe
antithrombotic therapy (eg, ability of patient to manage therapy,
relative contraindications to therapy) were documented for each
patient.
Data analysis
Computerized data analysis of patient outcomes was performed by
using SPSS Statistics 20 (IBM Corp). Analysis of variance tested
for  mean  differences  in  continuous  variables,  and  the  χ2  test,
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Mann–Whitney U test, and Kruskal–Wallis test examined differ-
ences in independent proportions (for parametric and nonparamet-
ric distributions, as appropriate). Multivariate logistic regression
analysis and generalized linear modeling identified predictors of
treatment use and prescribing changes in the total patient sample,
including the contribution of CARAT. We adjusted for selected
covariates (eg, patient characteristics, including levels of risk) and
clustering of patients by GPs according to the level of variability
in the initial analyses (eg, inclusion of intercepts for patients nes-
ted within GP practices). However, the lack of variability in the
control arm of primary outcomes (ie, no changes in treatment use)
precluded specific analyses. Simpler analyses focused on treat-
ment changes in the intervention arm (before and after measures).
Forward stepwise (Wald) regression was used because of the large
number of potential explanatory variables for the outcome. For-
ward selection of variables begins with no variables in the initial
model, then adds variables in succession, with iterative testing to
see how each variable addition improves the model. In this study,
any variable found to be independently associated with the out-
come variable during univariate analysis (P < .10) was applied to
the multivariate model. The Fleiss κ statistic assessed the level of
agreement between the CARAT recommendations and the GP’s
final decision on antithrombotic therapy (22–24). All analyses
were set at a significance level of .05 (unless otherwise specified),
assuming intention-to-treat.
Results
A total of 393 AFib patients (mean [standard deviation] age, 78.0
[7.0] y) were recruited into the study by 48 GPs; 25 GPs and 206
patients were randomized into the intervention arm (Table 1). We
found no significant differences in patient characteristics between
the study arms or across the 4 regions, except that patients in the
control arm had fewer chronic conditions than patients in the inter-
vention arm (5.4 vs 6.1, P = .01).
Overall, 70.7% of patients were assessed as being at high risk of
stroke; the most common risk factors were hypertension (68.2%)
and being aged 75 or older (67.7%). Only 1.0% of patients were
assessed as being at high risk of bleeding; the most common risk
factors were uncontrolled hypertension (10.2%) and malignancy
(8.4%) (Table 2). A higher proportion of patients in the control
arm (11.2%) were deemed to be at low risk of stroke than the pro-
portion in the intervention arm (2.9%) (P < .001).  Two-thirds
(67.9%) of all patients were deemed to be at high risk of stroke
and at low risk of bleeding (ie, most eligible for antithrombotic
therapy).
We found no significant differences between the 2 arms in factors
affecting the decision to prescribe antithrombotic therapy (Table
3). Overall, the most common medication-safety considerations
were  patients  taking  4  or  more  medications  (94.4%),  patients
needing assistance with medication management (41.0%), and
functional impairment (16.0%). Although most patients were tak-
ing 4 or more medications,  only 5.6% had a known history of
medication nonadherence. Most patients (96.7%) had been edu-
cated about their antithrombotic therapy; only 1.3% of patients
had previously declined therapy.
At baseline, 387 patients (98.5%) used some form of antithrom-
botic therapy: 361 (91.9%) used an anticoagulant (warfarin [± an-
tiplatelet] or dabigatran [± clopidogrel]), 26 (6.6%) used antiplate-
let therapy (aspirin only or clopidogrel only), and 6 (1.5%) did not
use any therapy (Figure 2). Most patients using antithrombotics
were prescribed warfarin (316/387; 81.7%); of these, 14 used war-
farin in combination with aspirin,  and 1 patient  each was pre-
scribed the combination of warfarin, aspirin, and clopidogrel or
warfarin and clopidogrel. The remaining patients were prescribed
dabigatran (± clopidogrel) (45/387; 11.6%), aspirin only (23/387;
5.9%), or clopidogrel only (3/387; 0.8%).
Figure 2. Changes in the use of antithrombotic therapy, by type of
therapy and by patient groups (intervention arm and control arm), in
a  cluster-randomized  control led  tr ial  of  a  computerized
antithrombotic risk assessment tool in a sample of general practices
in New South Wales, Australia, 2012–2013. Percentages may not
total 100 because of rounding.
 
At baseline, the use of anticoagulants was similar between pa-
tients in the control arm (177/187; 94.7%) and intervention arm
(184/206; 89.3%) (P = .38) as was the use antiplatelet therapy (6/
187 [3.2%] in control arm vs 20/206 [9.7%] in intervention arm; P
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= .10). Although the difference was not significant, a greater pro-
portion of patients in the control arm (162/187; 86.6%) used war-
farin  (±  antiplatelet)  than  in  the  intervention  arm  (154/206;
74.8%),  and  a  smaller  proportion  in  the  control  arm (15/187;
8.0%) used dabigatran (± clopidogrel) than in the intervention arm
(30/206; 14.6%).
In the intervention arm, all 206 patients were recommended some
form of antithrombotic therapy by CARAT; no patient was recom-
mended no therapy. Overall, CARAT recommended a different
type of therapy or agent for 75 (36.4%) patients; for 1 other pa-
tient, the change was to increase the dose of warfarin to achieve
therapeutic levels at the recommended target international normal-
ized  ratio.  Among the  75  CARAT-recommended  changes,  12
(16.0%) were upgrades to a more effective prophylactic therapy
(ie, from no therapy to any agent, or from aspirin to warfarin or
dabigatran), whereas 35 (46.7%) were classified as “side-steps” to
different agents in the same category of therapy (eg, from one an-
ticoagulant to another, or from the combination of warfarin and as-
pirin to warfarin only). The remaining 28 (37.3%) recommenda-
tions were downgrades to less effective but potentially safer op-
tions (ie, from any agent to no therapy, or from warfarin and dabi-
gatran to aspirin). Among the 6 patients using the combination of
warfarin and aspirin for whom CARAT recommended changes,
CARAT recommended changing the therapy to warfarin only for
all but one patient (who was recommended aspirin only).
GPs agreed with most (75.2%) CARAT recommendations for the
206 patients in the intervention arm (κ = 0.91; P = .03). Overall,
for the 75 recommended changes, GPs agreed with the type of
therapy (ie, antiplatelet vs anticoagulant) suggested by CARAT in
48 (64.0%) cases. However, among these 48 cases, GPs disagreed
with CARAT on the agent recommended in 30 (62.5%) cases, all
relating to the GP preferences for dabigatran over the CARAT-re-
commended warfarin. Among the 35 recommendations for warfar-
in-only therapy, GPs agreed in 13 cases; most GPs instead pre-
scribed dabigatran (19 cases) followed by aspirin (2 cases), and 1
patient received no therapy. The most common reasons cited for
disagreeing with CARAT’s recommendations were “treatment
considered inappropriate” and “following the cardiologist’s re-
commendation.” In the northern suburbs of Sydney, the main reas-
on for declining CARAT’s recommendation was participation in
the Pradaxa (dabigatran) product familiarization program, regard-
less of whether the NOAC was appropriately indicated or not. Per-
ceived patient refusal was cited as a reason to decline CARAT re-
commendations in 8 of 48 (16%) intervention patients (ranging
from 6.7% to 33.3% across practice regions); however, according
to clinical notes, only 4 (1.9%) intervention patients declined ther-
apy previously (Table 3).
GPs initiated changes to therapy only among intervention patients
flagged by CARAT as needing a change; GPs did not make any
changes to therapy for the 131 patients for whom CARAT did not
recommend a change. Overall, the net effect of these changes was
that  the  use  of  antithrombotic  therapy  did  not  change  from
baseline (204/206; 99.0%), but the use of anticoagulants increased
significantly (P = .02) from 89.3% (184/206) to 92.2% (190/206),
and the use of antiplatelet therapy decreased (but not significantly
[P = .20]) from 9.7% (20/206) to 6.8% (14/206) (Figure 2). None
of the 3 patients using clopidogrel at baseline used it after applica-
tion of CARAT: 2 patients were prescribed dabigatran and 1 was
prescribed warfarin and aspirin. These changes are net changes in
the proportion of patients using these antithrombotics, taking into
account all upgrades, downgrades, and side-steps in treatment. We
found more CARAT recommendations for downgrades to less ef-
fective but potentially safer options than for upgrades to more ef-
fective prophylactic therapy.
Overall, a significantly higher proportion of patients in the inter-
vention arm (36.9%; 76/206) than in the control arm (0%; 0/187)
were assessed for potential changes to therapy during baseline
consultations (P < .001); 9 (4.4%; 9/206) patients in the interven-
tion arm and none in the control arm immediately changed their
therapy (P = .003).
Overall, compared with patients in the control arm, patients in the
intervention arm were 3.1 times more likely to be considered for
warfarin therapy (in preference to other treatment options; P <
.001) and 2.8 times more likely to receive an anticoagulant (in
preference to an antiplatelet; P = .02) (Table 4).
Discussion
GPs in local Australian practices are increasingly prescribing anti-
thrombotic therapy for stroke prevention in patients with AFib, in
line with current guidelines and in response to interventions imple-
mented during the past decade to improve clinician awareness,
better support patients and clinicians in managing anticoagulant
therapy, and develop newer treatment options. Overall, the high
use of  antithrombotics (any therapy) in this  cohort  of  patients
demonstrates that tools such as CARAT may have a limited role in
the initial decision to prescribe therapy; however, the choice of
agents may require further support, as evidenced by the propor-
tion of patients receiving antiplatelet therapy or dabigatran, and
which may reflect persistent reservations about warfarin use. This
is an interesting finding, given that the prevalence of contraindica-
tions to warfarin and any related medication safety considerations
that are often cited as reasons to avoid warfarin (eg, falls risk,
functional/cognitive impairment) was low in this study. Most pa-
tients were assessed as being at high risk of stroke and at low risk
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of bleeding and therefore were ideal candidates for anticoagula-
tion  therapy with  warfarin.  More  important  was  that  CARAT
helped to rationalize therapy rather than simply increasing therapy:
the tool helped to review a patient’s existing therapy and accoun-
ted for any changes in risk (for both stroke and bleeding) and de-
velopment  of  contraindications;  this  process  resulted  in  more
downgrades (to safer options) than upgrades (to more effective op-
tions) in therapy. Studies have similarly shown this effect when re-
view processes and tools are not only applied in the initial de-
cision to prescribe therapy but also in reviewing a patient’s ongo-
ing therapy (14).
Although the application of CARAT did not result in dramatic im-
provements in the net use of antithrombotic therapy in this study,
because of the high use of anticoagulants at baseline, the level of
agreement on recommendations between CARAT and GPs is en-
couraging. However, the GPs agreeing to participate in this study
may have been more confident in their evidence-based practice in
antithrombotic therapy than GPs not agreeing to participate, and
this potential selection bias may have contributed to the unexpec-
tedly high level of concordance with antithrombotic guidelines.
Nevertheless, CARAT assisted with rationalization of therapy and
identified several lingering issues, such as patient refusal, that ap-
pear  to  preclude further  improvement  in  care;  future  research
should explore how adherence to therapy can be better supported
and how clinicians can better engage patients in the decision-mak-
ing process.
Since this study was conducted, the NOACs (dabigatran, rivar-
oxaban, apixaban) have become available for widespread use (at
the Australian Pharmaceutical Benefits Scheme’s subsidized costs)
and have complicated decision-making further, necessitating guid-
ance on how to select a therapy (5,7). Although these new agents
offer several advantages, each has risks; safety alerts have de-
scribed the risks of over-zealous, indiscriminate use (27). In this
study, numerous patients who were recommended warfarin by
CARAT received dabigatran instead, with no obvious rationale for
dabigatran’s selection.  Dedicated tools may be needed to help
clinicians identify patients who would benefit from NOAC ther-
apy and to select which type to use; for this reason, a modified
version of the CARAT is in development. How the high costs of
NOACs may affect prescribing patterns should be considered. Al-
though NOACs were found to be cost-effective alternatives to
warfarin for stroke prevention in patients with AFib (28), studies
showed that the absolute, short-term costs of NOACs can affect
treatment selection. For example, a Canadian study demonstrated
socioeconomic inequality in access to dabigatran among patients
receiving warfarin for nonvalvular AFib; in the absence of sub-
sidies,  patients  in the highest  income quintile  were 50% more
likely to switch from warfarin to dabigatran than those in the low-
est  income  quintile  (29).  When  such  disparity  is  eliminated
through  subsidies,  treatment  costs  challenge  health-system
budgets. In Australia, high-cost medicines such as NOACs are
subsidized  by  the  Australian  Pharmaceutical  Benefit  Scheme,
making them affordable for patients but costly for government.
Concerns about the costs of NOACs led the Australian govern-
ment to re-examine the selection of therapy (7). In this study, pre-
scribing patterns were likely not affected by the differential costs
of treatments because of subsidies. However, decision-support
tools  such  as  CARAT  may  need  to  consider  how  costs  are
weighed in the decision-making processes of the diverse econom-
ic and health-systems contexts in which therapies are used.
This study had several limitations. First, data extraction relied on
GP responses and clinical records; records may have been out-
dated or incomplete, and explanations for the use of therapy may
not have been recorded. In particular, the patient’s AFib status was
determined by GP verification; however, the proportion of pa-
tients with new onset AFib (in whom the need for long-term anti-
thrombotic therapy may not initially be clear) was low (5.6%) and
had no significant effect on overall treatment use. Second, routine
anticoagulation therapy may not be indicated for all cases of new
onset AFib, such as post-surgical AFib, and so the role of CAR-
AT may be limited in this context (30). Third, this study was de-
signed to explore the use of therapy according to prescription by
clinicians; it did not examine the extent to which patients adhered
to the treatments prescribed.
CARAT was designed only to consider antithrombotics available
at the time of the study (ie, warfarin, aspirin), and it may not have
accounted for other factors important to decision-making, such as
patients preferences (eg, warfarin vs NOAC), affordability, and
access to resources to support clinicians and patients in managing
treatment  options.  The  availability  of  dabigatran  through  the
product familiarization program may have clouded decision mak-
ing in some cases, and the full impact of CARAT may not have
been realized. The availability of dabigatran through the product
familiarization program may have motivated some clinicians to try
it, regardless of CARAT’s recommendation. Concerns about the
product familiarization program and possible inappropriate use of
dabigatran have been raised (31). The inability of CARAT to re-
commend a NOAC as a treatment option or provide practical ad-
vice to clinicians about the suitability of dabigatran for a patient
may have affected the rate of uptake of CARAT recommenda-
tions. A higher proportion of control-arm patients than interven-
tion-arm patients were deemed to be at low risk of stroke; overall,
this difference did not appear to influence the likelihood of receiv-
ing treatment, according to the multivariate analyses. Collectively,
the above-mentioned issues may have affected the impact of CAR-
AT and the patterns of antithrombotic use observed in this study.
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Despite  these limitations,  this  study showed that  CARAT im-
proved the use of antithrombotic therapy by supporting the ration-
alization of therapy. Tools such as CARAT support decision mak-
ing by assisting in selecting a therapy, particularly in upgrading a
patient from an antiplatelet agent to an anticoagulant. The advent
of NOACs has further complicated decision making, and decision-
support tools must evolve to weigh the risks and benefits of these
new therapy options.
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Tables
Table 1. Characteristics of Patients With Atrial Fibrillation in Intervention and Control Arms of a Cluster-Randomized Controlled Trial of a Compu-
terized Antithrombotic Risk Assessment Tool for General Practitioners in New South Wales, Australiaa,b
Characteristic All Patients Intervention Arm Control Arm P Valuec
No. of patients (% of total sample) 393 (100.0) 206 (52.4) 187 (47.6) —
Age, mean (SD), y 78.0 (7.0) 78.2 (7.1) 77.7 (7.0) .52
Age group
≥80 y 180 (45.8) 96 (46.6) 84 (44.9)
.74
<80 y 213 (54.2) 110 (53.4) 103 (55.1)
Sex
Male 214 (54.5) 113 (54.9) 101 (54.0)
.87
Female 179 (45.5) 93 (45.1) 86 (46.0)
No. of chronic conditions, mean (SD) 5.8 (2.5) 6.1 (2.7) 5.4 (2.3) .01
No. of prescription medications, mean (SD) 9.2 (4.0) 9.0 (3.7) 9.4 (4.3) .42
No. of nonprescription medications, mean (SD) 1.5 (1.3) 1.5 (1.3) 1.5 (1.3) .94
History of atrial fibrillation
<3 mo 10 (2.5) 7 (3.4) 3 (1.6)
.24
<12 mo 39 (9.9) 20 (9.7) 19 (10.2)
<2 y 59 (15.0) 25 (12.1) 34 (18.2)
<5 y 82 (20.9) 49 (23.8) 33 (17.6)
≥5 y 203(51.7) 105 (51.0) 98 (52.4)
Type of atrial fibrillation
Paroxysmal 139 (35.4) 76 (36.9) 63 (33.7)
.86
Persistent 224 (57.0) 116 (56.3) 108 (57.8)
New onset 22 (5.6) 10 (4.9) 12 (6.4)
Unknown 8 (2.0) 4 (1.9) 4 (2.1)
Duration of persistent atrial fibrillation, mean (SD), y 6.8 (6.8) 6.0 (3.7) 7.7 (8.9) .01
Previous hospitalization for atrial fibrillation
No 259 (65.9) 134 (65.0) 125 (66.8)
.71
Yes 134 (34.1) 72 (35.0) 62 (33.2)
Reason for previous hospitalization
Management of atrial fibrillation 87 (64.9) 48 (66.7) 39 (62.9)
.85Stroke or cerebrovascular accident from atrial fibrillation 24 (17.9) 13 (18.1) 11 (17.7)
a All values are number (percentage in subgroup) unless otherwise indicated.
b General practitioners were recruited from 4 regions of general practice in New South Wales, Australia: the northern suburbs of Sydney, the
Central Coast, the Newcastle metropolitan area (in the Hunter Region), and the rural areas of the Hunter Region. Each general practitioner (25 in
control arm and 25 in intervention arm) recruited 5 to 10 patients.
cP value for difference between intervention arm and control arm determined by Pearson χ2 test.
d Includes acute myocardial infarction, amiodarone-induced hyperthyroidism, anterior resection, aortic valve replacement, carcinoma, cardiac ab-
lation, pacemaker reinsertion, pulmonary embolism.
(continued on next page)
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(continued)
Table 1. Characteristics of Patients With Atrial Fibrillation in Intervention and Control Arms of a Cluster-Randomized Controlled Trial of a Compu-
terized Antithrombotic Risk Assessment Tool for General Practitioners in New South Wales, Australiaa,b
Characteristic All Patients Intervention Arm Control Arm P Valuec
Transient ischemic attack 12 (9.0) 5 (6.9) 7 (11.3)
Otherd 11 (8.2) 6 (8.3) 5 (8.1)
Current cardiac rhythm
Normal sinus rhythm 45 (11.5) 25 (12.1) 20 (10.7)
.57Controlled atrial fibrillation 347 (88.3) 180 (87.4) 167 (89.3)
Uncontrolled atrial fibrillation 1 (0.3) 1 (0.5) 0 (0.0)
a All values are number (percentage in subgroup) unless otherwise indicated.
b General practitioners were recruited from 4 regions of general practice in New South Wales, Australia: the northern suburbs of Sydney, the
Central Coast, the Newcastle metropolitan area (in the Hunter Region), and the rural areas of the Hunter Region. Each general practitioner (25 in
control arm and 25 in intervention arm) recruited 5 to 10 patients.
cP value for difference between intervention arm and control arm determined by Pearson χ2 test.
d Includes acute myocardial infarction, amiodarone-induced hyperthyroidism, anterior resection, aortic valve replacement, carcinoma, cardiac ab-
lation, pacemaker reinsertion, pulmonary embolism.
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Table 2. Risk Factors and Level of Assessed Risk Among Patients With Atrial Fibrillation in Intervention and Control Arms of a Cluster-Randomized
Controlled Trial of a Computerized Antithrombotic Risk Assessment Tool for General Practitioners in New South Wales, Australiaa
Risk Factor and Level All Patients (N = 393)
Intervention Arm (n =
206)




Previous stroke or transient ischemic attack 72 (18.3) 50 (24.3) 22 (11.8) .001
Aged ≥75 y 266 (67.7) 151 (73.3) 115 (61.5) .01
Congestive heart failure 100 (25.4) 84 (40.8) 16 (8.6) <.001
Hypertension 268 (68.2) 166 (80.6) 102 (54.5) <.001
Diabetes mellitus 78 (19.8) 41 (19.9) 37 (19.8) 0.98
Level of assessed risk
High 278 (70.7) 175 (85.0) 103 (55.1)
<.001Intermediate 88 (22.4) 25 (12.1) 63 (33.7)
Low 27 (6.9) 6 (2.9) 21 (11.2)
Bleeding Riskd
Risk factor
Hepatic or renal disease 18 (4.6) 12 (5.8) 6 (3.2) .22
Alcohol abuse 8 (2.0) 7 (3.4) 1 (0.5) .045
Malignancy 33 (8.4) 22 (10.7) 11 (5.9) .09
Reduced platelet count 6 (1.5) 6 (2.9) 0 (0.0) .02
Re-bleeding risk 4 (1.0) 4 (1.9) 0 (0.0) .06
Uncontrolled hypertension 40 (10.2) 13 (6.3) 27 (14.4) .008
Anemia 14 (3.6) 9 (4.4) 5 (2.7) .36
Risk of excessive falls 22 (5.6) 22 (10.7) 0 (0.0) <.001
Previous hemorrhagic stroke 6 (1.5) 6 (2.9) 0 (0.0) .02
Level of assessed risk
High 4 (1.0) 4 (1.9) 0 (0.0)
.03Intermediate 10 (2.5) 8 (3.9) 2 (1.1)
Low 379 (96.4) 194 (94.2) 185 (98.9)
a All values are number (percentage in subgroup) unless otherwise indicated.
bP value for difference between intervention arm and control arm determined by Pearson χ2 test.
c Patients were assessed for risk of stroke according to the CHADS2 Score for Atrial Fibrillation Stroke Risk (25).d Patients were assessed for risk of bleeding according to HEMORR2HAGES criteria (26).
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Table 3. Medication-Safety and Medication-Management Assessments in the Intervention and Control Arms of a Cluster-Randomized Controlled
Trial of a Computerized Antithrombotic Risk Assessment Tool for General Practitioners in New South Wales, Australiaa
Assessment
All Patients (N =
393) Intervention Arm (n = 206) Control Arm (n = 187) P Valueb
Medication safety
Patient allergic to warfarin and aspirin 8 (2.0) 6 (2.9) 2 (1.1) .22
Adverse reaction to antithrombotics 15 (3.8) 9 (4.4) 6 (3.2) .52
Taking medication that interacts with warfarin 1 (0.3) 1 (0.5) 0 (0.0) .73
Patient has declined antithrombotics 5 (1.3) 4 (1.9) 1 (0.5) .38
Patient has contraindication to antithrombotics 11 (2.8) 5 (2.4) 6 (3.2) .76
Patient has failed antithrombotics 10 (2.5) 6 (2.9) 4 (2.1) .75
Patient received education about antithrombotics 380 (96.7) 198 (50.4) 182 (47.9) .58
Medication management
Patient taking ≥4 medications 371 (94.4) 195 (94.7) 176 (94.1) .83
Patient is not compliant with medication 22 (5.6) 8 (3.9) 14 (7.5) .13
Patient needs assistance for medication
management
161 (41.0) 83 (40.3) 78 (41.7) .84
Difficulty accessing medical care 3 (0.8) 1 (0.5) 2 (1.1) .61
Patient in residential care facility 4 (1.0) 2 (1.0) 2 (1.1) >.99
Cognitive impairment 18 (4.6) 8 (3.9) 10 (5.3) .63
Vision impairment 24 (6.1) 15 (7.3) 9 (4.8) .40
Hearing impairment 34 (8.7) 18 (8.7) 16 (8.6) >.99
Language/communication barrier 4 (1.0) 2 (1.0) 2 (1.1) >.99
Mobility disorder 17 (4.3) 9 (4.4) 8 (4.3) >.99
Functional impairment 63 (16.0) 26 (12.6) 37 (19.8) .06
a All values are number (percentage in subgroup) unless otherwise indicated.
bP value for difference between intervention arm and control arm determined by Pearson χ2 test.
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Table 4. Predictors of the Use of Antithrombotic Therapy (Multivariate Model) Post-Intervention (N = 393) in a Cluster-Randomized Controlled Tri-
al of a Computerized Antithrombotic Risk Assessment Tool (CARAT) for General Practitioners in New South Wales, Australia
Variable Odds Ratio (95% Confidence Interval)
Model A: Predictors of the use of anticoagulant therapy in preference to antiplatelet therapya
Use of CARAT for decision making in the intervention arm (vs control arm) 2.8 (1.1–7.3)b
History of uncontrolled hypertension 3.5 (1.4–8.3)b
Previous hemorrhagic stroke 0.1 (0.02–0.7)
Model B: Predictors of the use of warfarin in preference to other treatment optionsc
Intervention arm decision making after application of CARAT (vs control arm) 3.1 (1.7–5.7)b
History of uncontrolled hypertension 2.4 (1.3–4.1)b
Excessive alcohol intake 0.2 (0.05–1.0)
Language barrier 0.1 (0.01–0.7)
Increasing number of prescription medications being used 0.8 (0.6–0.9)
Increasing number of nonprescription medications being used 0.8 (0.6–1.0)
Malignancy 0.4 (0.2–0.8)
Previous hemorrhagic stroke 0.2 (0.3–0.97)
a Model correctly classified 93.5% of cases. Cox and Snell R2 = 0.43; Nagelkerke R2 = 0.11.
b More likely to receive the former therapy; analyses adjusted for selected factors.
c Model correctly classified 81.4% of cases. Cox and Snell R2 = 0.12; Nagelkerke R2 = 0.19.
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